Dr. Sara Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. She is particularly interested in the development and testing of new targeted therapies for the treatment of breast cancer. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.